Lead Product(s): Bromelain
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Highest Development Status: Approved Product Type: Large molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 04, 2020
MediWound granted GENFA MEDICA SA right to distribute NexoBrid® in France and Switzerland and Specialty Therapeutics the right to market and distribute NexoBrid in Greece, Bulgaria, Malta and Cyprus.